The Food and Drug Administration expects to complete its safety review of mifepristone by March 2027, according to a federal court filing that could shape the future of medication-abortion access. Reuters reports that the agency is examining potential risks through a comparison involving 100,000 patients who used mifepristone and a group who underwent surgical abortions. The review could provide a basis for reconsidering regulations permitting remote prescriptions and mail delivery. Major medical organizations maintain that the medication is safe and effective when used as directed. Medication abortion accounted for approximately 65% of U.S. abortions in 2023, making any future regulatory restrictions consequential for patients and providers. No new restriction has been announced, but the agency’s timeline establishes a clearer point at which existing access rules could change.